Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Cell transfection, Western blot etc. |
| Sample | pancreatic cancer tissues, cell line (PANC-1) |
| Expression Pattern | down-regulated |
| Function Description | The MEG 3 was negatively correlated with tumor size, Metastasis and Vascular invasion in pancreatic cancer. In the cell experiment, The cell proliferation and apoptosis rates of lncRNA group were significantly difference compared with NC group, and the G1 phase rate of lncRNA group was higher than NC group. The invasion cells and wound healing rate were significantly reduced in lncRNA group than those in NC group. |
| Pubmed ID | 28320094 |
| Year | 2017 |
| Title | lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |